96232-41-6

Usage

Uses

Used in Medicinal Chemistry:
2-[(DIMETHYLAMINO)METHYLENE]-3-(4-METHYLPHENYL)-3-OXO-PROPANENITRILE is used as a building block for the synthesis of pharmaceuticals and agrochemicals. Its unique chemical structure allows for the development of new compounds with potential therapeutic and pesticidal properties.
Used in Organic Chemistry Research:
Due to its distinctive chemical features, 2-[(DIMETHYLAMINO)METHYLENE]-3-(4-METHYLPHENYL)-3-OXO-PROPANENITRILE is utilized in organic chemistry research to explore novel reactions and mechanisms. This can lead to the discovery of new synthetic pathways and the creation of innovative organic compounds.
Used in Material Science:
2-[(DIMETHYLAMINO)METHYLENE]-3-(4-METHYLPHENYL)-3-OXO-PROPANENITRILE may also be of interest in material science for its potential to contribute to the development of new materials with unique properties. Its incorporation into polymers or other materials could result in novel applications in various industries.
Further studies on the properties and potential uses of 2-[(DIMETHYLAMINO)METHYLENE]-3-(4-METHYLPHENYL)-3-OXO-PROPANENITRILE are necessary to fully understand its capabilities and harness its potential in these and other applications.

InChI:InChI=1/C13H14N2O/c1-10-4-6-11(7-5-10)13(16)12(8-14)9-15(2)3/h4-7,9H,1-3H3/b12-9+

Upstream product

• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 7391-28-8 p-tolueneacetonitrile 

Relevant academic research and scientific papers

Pyrazolo[3,4-b]pyridine in heterocyclic synthesis: Synthesis of new pyrazolo[3,4-b]pyridines, imidazo[1′,2′:1,5]pyrazolo[3,4-b] pyridines, and pyrido[2′,3′:3,4]pyrazolo[1,5-a]pyrimidines

Pyrazolo[3,4-b]pyridine derivatives 7 and 9 were synthesized via the reaction of 3-amino-1H-pyrazolo-[3,4-b]pyridine derivative 2 with ω-bromoacetophenones. Reaction of 7 and 9 with Ac2O afforded the imidazo[1′,2′:1,5]pyrazolo[3,4-b]pyridine derivative 8 and pyrazolo[3,4-b]pyridine derivative 10, respectively. Reaction of 2 with chloroacetonitrile followed by DMF-DMA gave imidazo[1′,2′:1,5] pyrazolo[3,4-b]pyridines 4 and 5, respectively. Acetylacetone and 1,1-dicyano-2,2-dimethylthioethene were reacted with 2 to afford the pyrido[2′,3′:3,4]pyrazolo-[1,5-a]-pyrimidines 11 and 14, respectively. Also, 2 reacted with DMF-DMA to yield the formamidine 15, which in turn, reacted with active methylene reagents, yielding the corresponding pyrido[2′,3′:3,4]pyrazolo[1,5-a]pyrimidines 18 and 23a-23d.

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)- 3(trifluoromethyl)-1h-pyrazol-1-yl]benzenesulfonamide (sc-58635, celecoxib)

A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC- 236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of 1i (4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-y1]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.